{"id":"y-2-sublingual-tablets","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypotension"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1476996","moleculeType":"Small molecule","molecularWeight":"366.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, there is limited information available on the exact mechanism of action of Y-2 sublingual tablets.","oneSentence":"Y-2 sublingual tablets' mechanism is not well-documented.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:41:09.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute ischemic stroke"}]},"trialDetails":[{"nctId":"NCT05940883","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-09-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT04950920","phase":"PHASE3","title":"Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2021-06-28","conditions":"Stroke","enrollment":914},{"nctId":"NCT03495206","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet","status":"UNKNOWN","sponsor":"Yantai YenePharma Co., Ltd.","startDate":"2018-10-25","conditions":"Stroke, Acute, Intracranial Hemorrhages","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Y-2 sublingual tablets","genericName":"Y-2 sublingual tablets","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Y-2 sublingual tablets are a small molecule intervention being studied in clinical trials for various conditions, including stroke and intracranial hemorrhages. The primary purpose of these trials is to evaluate the pharmacokinetics, safety, and tolerability of Y-2 sublingual tablets in healthy adult subjects and potentially in patients with stroke and intracranial hemorrhages.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}